Our Associate Director of Clinical Research, Christopher Lieu, MD, discusses how performance status, prior toxicities, and molecular biomarkers guide individualized third‑line treatment strategies for patients with refractory metastatic colorectal cancer.
CU Anschutz
Anschutz Cancer Pavilion
1665 North Aurora Court
2004
Aurora, CO 80045